The greater reliance of pathogenic Th17 cells on STIM1 and OXPHOS may be exploitable for the treatment of autoimmune diseases in which pathogenic Th17 cells play an important role without affecting the antimicrobial function of non‐pathogenic Th17 cells. This evidence concerns the gene STIM1 and autoimmune disease.